Przychodzen Bartlomiej, Makishima Hideki, Sekeres Mikkael A, Balasubramanian Suresh Kumar, Thota Swapna, Patel Bhumika J, Clemente Michael, Hirsch Cassandra, Dienes Brittney, Maciejewski Jaroslaw P
Department of Translational Hematology and Oncology Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Oncotarget. 2017 Dec 16;9(2):2050-2057. doi: 10.18632/oncotarget.23328. eCollection 2018 Jan 5.
Using next generation sequencing we have systematically analyzed a large cohort of 489 patients with bone marrow failure (BMF), including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), aplastic anemia (AA), and related conditions for the presence of germline (GL) alterations in Fanconi Anemia (FA) and telomerase genes. We have detected an increased frequency of heterozygous FA gene mutations in MDS and to lesser degree in AML suggesting that the presence of one normal allele may not be completely protective and indeed heterozygous FA lesions may have a long latency period before hematologic manifestation. In contrast, GL telomerase gene mutations were not associated with increased disease risk. When compared to large control cohorts, we have not detected an increased frequency of damaging variants among telomerase complex genes, including those previously believed to be involved in the pathogenesis of AA. Our results may suggest that while low penetrance and delayed disease onset can confound identification of genetic predisposition factors, GL FA alterations can be also associated with MDS.
我们使用新一代测序技术,系统分析了489例骨髓衰竭(BMF)患者的大样本队列,这些患者包括骨髓增生异常综合征(MDS)、急性髓系白血病(AML)、再生障碍性贫血(AA)以及相关病症,以检测范可尼贫血(FA)和端粒酶基因中种系(GL)改变的存在情况。我们在MDS中检测到杂合性FA基因突变频率增加,在AML中也有较小程度的增加,这表明一个正常等位基因的存在可能无法提供完全保护,实际上杂合性FA病变在血液学表现出现之前可能有很长的潜伏期。相比之下,GL端粒酶基因突变与疾病风险增加无关。与大型对照队列相比,我们在端粒酶复合基因中未检测到有害变异频率增加,包括那些先前认为与AA发病机制有关的基因。我们的结果可能表明,虽然低外显率和疾病发病延迟可能会混淆遗传易感性因素的识别,但GL FA改变也可能与MDS相关。